RU2019101166A - Композиции полисахаридов и способы применения - Google Patents
Композиции полисахаридов и способы применения Download PDFInfo
- Publication number
- RU2019101166A RU2019101166A RU2019101166A RU2019101166A RU2019101166A RU 2019101166 A RU2019101166 A RU 2019101166A RU 2019101166 A RU2019101166 A RU 2019101166A RU 2019101166 A RU2019101166 A RU 2019101166A RU 2019101166 A RU2019101166 A RU 2019101166A
- Authority
- RU
- Russia
- Prior art keywords
- ica
- pathogen
- pga
- pnag
- free
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims 19
- 229920001282 polysaccharide Polymers 0.000 title claims 19
- 239000005017 polysaccharide Substances 0.000 title claims 19
- 238000000034 method Methods 0.000 title claims 5
- 239000000203 mixture Substances 0.000 title claims 5
- 244000052769 pathogen Species 0.000 claims 98
- 230000001717 pathogenic effect Effects 0.000 claims 98
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 208000015181 infectious disease Diseases 0.000 claims 20
- 241000222122 Candida albicans Species 0.000 claims 16
- 229940095731 candida albicans Drugs 0.000 claims 16
- 241000194017 Streptococcus Species 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 9
- 230000001939 inductive effect Effects 0.000 claims 9
- 201000008827 tuberculosis Diseases 0.000 claims 9
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims 8
- 241000228212 Aspergillus Species 0.000 claims 8
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 8
- 241000233866 Fungi Species 0.000 claims 8
- 241000223218 Fusarium Species 0.000 claims 8
- 201000009906 Meningitis Diseases 0.000 claims 8
- 241000588653 Neisseria Species 0.000 claims 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 8
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 8
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 244000045947 parasite Species 0.000 claims 8
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 7
- 241000606124 Bacteroides fragilis Species 0.000 claims 7
- 241000589876 Campylobacter Species 0.000 claims 7
- 241000949031 Citrobacter rodentium Species 0.000 claims 7
- 241000193163 Clostridioides difficile Species 0.000 claims 7
- 241000606768 Haemophilus influenzae Species 0.000 claims 7
- 241000589989 Helicobacter Species 0.000 claims 7
- 241000186781 Listeria Species 0.000 claims 7
- 241000187480 Mycobacterium smegmatis Species 0.000 claims 7
- 241000223960 Plasmodium falciparum Species 0.000 claims 7
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 7
- 241000607626 Vibrio cholerae Species 0.000 claims 7
- 241000194033 Enterococcus Species 0.000 claims 6
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000013611 chromosomal DNA Substances 0.000 claims 6
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 6
- 238000007910 systemic administration Methods 0.000 claims 6
- 230000000699 topical effect Effects 0.000 claims 5
- 206010035500 Plasmodium falciparum infection Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241000588626 Acinetobacter baumannii Species 0.000 claims 3
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims 3
- 241000588780 Bordetella parapertussis Species 0.000 claims 3
- 241000588832 Bordetella pertussis Species 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 3
- 241000371430 Burkholderia cenocepacia Species 0.000 claims 3
- 241001646389 Burkholderia dolosa Species 0.000 claims 3
- 241000283707 Capra Species 0.000 claims 3
- 241000283073 Equus caballus Species 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 3
- 241001494479 Pecora Species 0.000 claims 3
- 241000009328 Perro Species 0.000 claims 3
- 241000288906 Primates Species 0.000 claims 3
- 241000282898 Sus scrofa Species 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 2
- 241000224527 Trichomonas vaginalis Species 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 235000013336 milk Nutrition 0.000 claims 2
- 210000004915 pus Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653389P | 2012-05-30 | 2012-05-30 | |
| US61/653,389 | 2012-05-30 | ||
| US201361827661P | 2013-05-26 | 2013-05-26 | |
| US61/827,661 | 2013-05-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152261A Division RU2014152261A (ru) | 2012-05-30 | 2013-05-30 | Композиции полисахаридов и способы применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019101166A true RU2019101166A (ru) | 2020-03-02 |
Family
ID=49673891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019101166A RU2019101166A (ru) | 2012-05-30 | 2013-05-30 | Композиции полисахаридов и способы применения |
| RU2014152261A RU2014152261A (ru) | 2012-05-30 | 2013-05-30 | Композиции полисахаридов и способы применения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152261A RU2014152261A (ru) | 2012-05-30 | 2013-05-30 | Композиции полисахаридов и способы применения |
Country Status (19)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2501077C (en) * | 2002-11-12 | 2016-06-21 | Gerald B. Pier | Polysaccharide vaccine for staphylococcal infections |
| PT1745075E (pt) | 2004-04-21 | 2013-06-17 | Brigham & Womens Hospital | Péptidos de ligação a poli-n-acetilglucosamina (pnag/dpnag) e métodos da sua utilização |
| CN105085349B (zh) | 2008-07-21 | 2018-02-09 | 布赖汉姆妇女医院 | 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物 |
| WO2016069888A1 (en) | 2014-10-29 | 2016-05-06 | University Of Wyoming | Compositions and methods for making and using hydrolytic enzymes for degrading polysaccharides made by foodborne pathogenic bacteria |
| MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
| CA3101239A1 (en) | 2018-05-23 | 2019-11-28 | Meharry Medical College | Glycan strand or oligosaccharide derived from gram-positive bacteria, method of making thereof and use thereof for inhibiting hiv or hbv replication (formerly: molecules derived from gram-positive bacteria) |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| CN110638830A (zh) * | 2019-09-29 | 2020-01-03 | 深圳市生命谷生命科技研究院 | 消化泥鳅多糖调节免疫功能或治疗免疫相关疾病的用途 |
| US11173199B2 (en) | 2019-11-13 | 2021-11-16 | Alopexx Inc. | Low contaminant compositions |
| KR20220107001A (ko) * | 2019-11-22 | 2022-08-01 | 알로펙스, 인크. | Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5565354A (en) | 1986-09-05 | 1996-10-15 | Sandoz Ltd. | Production of human monoclonal antibodies specific for hepatitis B surface antigen |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| ATE400296T1 (de) | 1999-12-02 | 2008-07-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung |
| CA2501077C (en) * | 2002-11-12 | 2016-06-21 | Gerald B. Pier | Polysaccharide vaccine for staphylococcal infections |
| PT1745075E (pt) * | 2004-04-21 | 2013-06-17 | Brigham & Womens Hospital | Péptidos de ligação a poli-n-acetilglucosamina (pnag/dpnag) e métodos da sua utilização |
| CN105085349B (zh) | 2008-07-21 | 2018-02-09 | 布赖汉姆妇女医院 | 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物 |
| US12397014B2 (en) * | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
-
2013
- 2013-05-30 SG SG10201609902YA patent/SG10201609902YA/en unknown
- 2013-05-30 SG SG10201911609XA patent/SG10201911609XA/en unknown
- 2013-05-30 CN CN201910419108.7A patent/CN110464839A/zh active Pending
- 2013-05-30 NZ NZ703260A patent/NZ703260A/en not_active IP Right Cessation
- 2013-05-30 EP EP13798089.2A patent/EP2854822B1/en active Active
- 2013-05-30 SG SG11201500428XA patent/SG11201500428XA/en unknown
- 2013-05-30 JP JP2015515176A patent/JP6403667B2/ja active Active
- 2013-05-30 KR KR1020147036646A patent/KR102282726B1/ko not_active Expired - Fee Related
- 2013-05-30 US US14/404,303 patent/US20150165016A1/en not_active Abandoned
- 2013-05-30 BR BR112014030025A patent/BR112014030025A2/pt not_active IP Right Cessation
- 2013-05-30 HK HK15109685.4A patent/HK1209031A1/xx unknown
- 2013-05-30 WO PCT/US2013/043283 patent/WO2013181348A1/en not_active Ceased
- 2013-05-30 MX MX2014014649A patent/MX2014014649A/es unknown
- 2013-05-30 CN CN201380040356.1A patent/CN104602696A/zh active Pending
- 2013-05-30 AU AU2013267444A patent/AU2013267444A1/en not_active Abandoned
- 2013-05-30 RU RU2019101166A patent/RU2019101166A/ru unknown
- 2013-05-30 CA CA3241764A patent/CA3241764A1/en active Pending
- 2013-05-30 ES ES13798089T patent/ES2826000T3/es active Active
- 2013-05-30 DK DK13798089.2T patent/DK2854822T3/da active
- 2013-05-30 RU RU2014152261A patent/RU2014152261A/ru not_active Application Discontinuation
- 2013-05-30 CA CA2879592A patent/CA2879592C/en active Active
-
2014
- 2014-11-27 IL IL235968A patent/IL235968B/en active IP Right Grant
- 2014-11-28 MX MX2019006620A patent/MX2019006620A/es unknown
- 2014-11-28 CL CL2014003276A patent/CL2014003276A1/es unknown
- 2014-12-01 PH PH12014502680A patent/PH12014502680A1/en unknown
-
2017
- 2017-09-27 JP JP2017186345A patent/JP6663402B2/ja active Active
-
2018
- 2018-03-14 AU AU2018201798A patent/AU2018201798A1/en not_active Abandoned
- 2018-12-07 JP JP2018229987A patent/JP2019059763A/ja active Pending
-
2020
- 2020-02-07 AU AU2020200908A patent/AU2020200908A1/en not_active Abandoned
-
2022
- 2022-03-02 AU AU2022201447A patent/AU2022201447B2/en active Active
-
2023
- 2023-12-01 US US18/526,557 patent/US20240358811A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019101166A (ru) | Композиции полисахаридов и способы применения | |
| Haas et al. | Understanding the virulence of Streptococcus suis: a veterinary, medical, and economic challenge | |
| US8529892B2 (en) | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions | |
| Ogunniyi et al. | The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo | |
| Tadepalli et al. | Fusobacterium necrophorum: a ruminal bacterium that invades liver to cause abscesses in cattle | |
| Lee et al. | Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis | |
| Fuhrmann et al. | Extracellular vesicles–A promising avenue for the detection and treatment of infectious diseases? | |
| Liu et al. | Dynamic changes in rumen fermentation and bacterial community following rumen fluid transplantation in a sheep model of rumen acidosis: implications for rumen health in ruminants | |
| JP2015521202A5 (cg-RX-API-DMAC7.html) | ||
| Lipinski et al. | A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits | |
| Paniagua-Contreras et al. | Comprehensive expression analysis of pathogenicity genes in uropathogenic Escherichia coli strains | |
| Mortazavi et al. | Recombinant PBP2a of methicillin-resistant S. aureus formulation in Alum and Montanide ISA266 adjuvants induced cellular and humoral immune responses with protection in Balb/C mice | |
| Li et al. | Weissella paramesenteroides NRIC1542 inhibits dextran sodium sulfate‐induced colitis in mice through regulating gut microbiota and SIRT1/NF‐κB signaling pathway | |
| AU2013353403B2 (en) | Vaccine for intrauterine disease | |
| Yoo et al. | Role of pneumococcal pneumolysin in the induction of an inflammatory response in human epithelial cells | |
| Schultz et al. | Escherichia coli Nissle 1917 | |
| Dheyab | Clinically important Yersinia: minireview | |
| Camussone et al. | Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant | |
| Bachtiar et al. | The effect of mouthwash combination of immunoglobulin–Y anti comD Streptococcus mutans and chitosan on the formation of Streptococcus mutans biofilm | |
| Al-Aalim | Immune Responses Induced by Standard and Extracted Lipopolysaccharide (LPS) from Escherichia coli | |
| Carvalho et al. | Breaking the bond: recent patents on bacterial adhesins | |
| Lei et al. | Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes | |
| Prescott | Gram‐Negative Anaerobes | |
| CA2246744C (fr) | Complexe immunomodulateur et son utilisation dans les affections par helicobacter | |
| CN102876620A (zh) | 一株无毒st28猪链球菌及其应用 |